Inactive Instrument

RayzeBio, Inc.

Equities

RYZB

US75525N1072

Biotechnology & Medical Research

RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million.

September 14, 2023 at 12:00 am EDT

RayzeBio, Inc. has completed an IPO in the amount of $310.9968 million.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 17,277,600
PriceRange: $18
Discount Per Security: $1.26

Transaction Features: Sponsor Backed Offering

Latest news about RayzeBio, Inc.

Certain Preferred Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Stock Options of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
Certain Common Stock of RayzeBio, Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024.	Mar. 12	CI
RayzeBio, Inc.(NasdaqGM:RYZB) dropped from S&P TMI Index	Feb. 27	CI
Bristol-Myers Squibb Completes RayzeBio Acquisition	Feb. 26	MT
Bristol Myers: acquisition of RayzeBio finalized	Feb. 26	CF
Rayzebio, Inc. Announces Executive Changes	Feb. 26	CI
RayzeBio, Inc.(NasdaqGM:RYZB) dropped from NASDAQ Composite Index	Feb. 25	CI
Bristol-Myers Squibb Company completed the acquisition of RayzeBio, Inc..	Feb. 25	CI
Wall Street: in the green after a euphoric Thursday	Feb. 23	CF
Bristol Myers Squibb Says RayzeBio Shareholders Overwhelmingly Accept $4.1 Billion Buyout Offer	Feb. 23	MT
Wall Street: stabilization in sight after a euphoric Thursday	Feb. 23	CF
Bristol Myers Wraps RayzeBio Tender Offer with 86% of Shares	Feb. 23	DJ
Bristol Myers: successful takeover bid for RayzeBio	Feb. 23	CF
PeptiDream to Partake in Bristol Myers' Tender Offer for All RayzeBio Shares	Feb. 15	MT
Bristol Myers Squibb Reportedly Eyeing $13 Billion from Bond Sale Launched Wednesday	Feb. 14	MT
Bristol-Myers Squibb, RayzeBio Say Hart-Scott-Rodino Act Waiting Period Expires	Feb. 12	MT
Bristol Myers: HSR period expires for RayzeBio	Feb. 12	CF
Bristol-Myers Squibb's New Product Performance Mixed as Headwinds Persist, Morgan Stanley Says	Feb. 05	MT
Bristol Myers posts better-than-expected 4th-quarter results	Feb. 02	RE
Bristol-Myers Squibb Plans 16 New Products by 2030, CEO says	Jan. 08	MT
Bristol Myers expects to launch 16 new products through 2030 - CEO	Jan. 08	RE
JPMorgan Downgrades RayzeBio to Neutral From Overweight, Adjusts Price Target to $62.50 From $30	Dec. 28	MT
Fusion Pharmaceuticals an 'Attractive' Takeover Target Following Recent Radiopharma Deals, Oppenheimer Says	Dec. 27	MT
Bristol-Myers Squibb's RayzeBio Deal Validates Value of SSTR2, Lung Cancer, B. Riley Says	Dec. 27	MT

Chart RayzeBio, Inc.

Duration

Period

More charts

Company Profile

RayzeBio, Inc. is a vertically integrated radiopharmaceutical therapeutics company. The Company is focused on building a somatostatin receptor type 2 (SSTR2) franchise. The Company's drug candidate, RYZ101, is designed to deliver a highly potent alpha particle radioisotope, Actinium 225 (Ac225), to tumors overexpressing SSTR2. RYZ101 consists of DOTATATE, a peptide binder, and a chelator, bound to Ac225, an alpha particle radioisotope. In addition to its SSTR2 franchise, the Company has discovered a peptide that selectively binds to Glypican-3 (GPC3), an oncofetal protein selectively overexpressed in hepatocellular carcinoma (HCC) as well as other cancers. The Company is enrolled in a registrational Phase III clinical trial of RYZ101 for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs) in patients who have experienced progression of their cancer following treatment with Lu177 therapy.

Sector

Biotechnology & Medical Research

Related indices

Russell 2000

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs